Skip to main content
Premium Trial:

Request an Annual Quote

Accelrys Inks Software Licensing Agreement with Gulf Coast Consortia


Accelrys said this week that it has signed a five-year licensing agreement with the Gulf Coast Consortia for Quantitative Biomedical Sciences that will give investigators in the group's chemical genomics program access to its scientific software, services, and training.

According to the company, its software will be used to support multi-disciplinary research and training programs for the treatment and prevention of diseases including rare and undertreated cancers.

The GCC will use the Accelrys Enterprise platform, which includes Accelrys Pipeline Pilot; the cloud-based Accelrys HEOS drug discovery information management workspace; the Accelrys Discovery Studio modeling and simulation application; and Accelrys Biological Registration software.

The GCC was founded by Baylor College of Medicine; Rice University; the University of Houston; the University of Texas Health Science Center, Houston; the University of Texas MD Anderson Cancer Center; and the University of Texas Medical Branch, Galveston.

Other members of the consortium include the Methodist Hospital Research Institute; the University of Texas, Austin; Texas A&M Health Science Center; Texas Southern University; and the University of Texas, El Paso.

Peter Davies, who directs the Center for Translational Cancer Research at Texas A&M Health Science Center and the GCC's chemical genomics program, said in a statement that the group selected the Accelrys platform because of its "plug-and-play deployment and ease of use in a seamless integrated network requiring minimal support by internal resources."

Michael Mancini, an associate professor in Baylor College of Medicine's molecular and cellular biology department and a co-director of the chemical genomics program, added that the group's assay development and screening programs have been using Pipeline Pilot for image analysis for several years.

"We are extremely pleased to now be able to integrate high content analysis/screening data and reporting across the entire program using HEOS," he said.

Filed under

The Scan

Booster Push

New data shows a decline in SARS-CoV-2 vaccine efficacy over time, which the New York Times says Pfizer is using to argue its case for a booster, even as the lower efficacy remains high.

With Help from Mr. Fluffington, PurrhD

Cats could make good study animals for genetic research, the University of Missouri's Leslie Lyons tells the Atlantic.

Man Charged With Threatening to Harm Fauci, Collins

The Hill reports that Thomas Patrick Connally, Jr., was charged with making threats against federal officials.

Nature Papers Present Approach to Find Natural Products, Method to ID Cancer Driver Mutations, More

In Nature this week: combination of cryogenic electron microscopy with genome mining helps uncover natural products, driver mutations in cancer, and more.